Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia
Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
The study will investigate in newly diagnosed CP-CML patients the efficacy of NIL frontline
therapy vs IM followed by switch to NIL in the case of absence of optimal response as defined
by the ELN criteria.